OakChart

Lisata Therapeutics Inc

LSTAHealthcare·Biotechnology·USA·Nano·NASD·Nov 11 • 3:59 PM ET

1.20+0.18 (17.65%)
2026-11-11 23:30 CET
Market cap
11.02 USD m
Revenue, TTM
0.10 USD m
Net income, TTM
-14.62 USD m
Free cash flow, TTM
-12.32 USD m
EPS diluted, TTM
-1.64
P/E
-
Compare

Price

LSTA against its 20, 50 and 200-day averages
2050200
1.002.003.004.003.6M7.1MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26LSTAclose 1.2020-day 1.0450-day 1.30200-day 2.901.2052w low

76.3% under the 52-week high of 5.07 on 10 Mar 2026. 52-week low 0.96 on 19 Oct 2026. Last 15 sessions, 48.8% high to low

Volume 3.74× normal · the line is the 50-bar volume average

Profile

LSTA
52-week range, 6% of the way up
0.965.07

Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company, which engages in the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other major diseases. Its product, Certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to target and penetrate tumors. The company was founded in 1980 and is headquartered in Liberty Corner, NJ.

Employees21
IPONov 03, 1995
Beta1.01
ATR, 14d0.13
Rel volume3.74
Short float0.42%
Insider own24.53%
Inst own11.06%

Snapshot

6 groups

Valuation

Index-
Market Cap12.96M
Enterprise Value2.27M
Income-14.62M
Sales0.10M
Book/sh0.90
Cash/sh0.97
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees21
IPONov 03, 1995

Ratios

P/E-
Forward P/E-
PEG-
P/S129.65
P/B1.33
P/C1.24
P/FCF-
EV/EBITDA-
EV/Sales22.75
Quick Ratio3.69
Current Ratio3.69
Debt/Eq0.00
LT Debt/Eq0.00
Option/ShortNo / Yes

Earnings

EPS (ttm)-1.64
EPS next Y-
EPS next Q-
EPS this Y-
EPS next Y-
EPS next 5Y-
EPS past 3/5Y43.29% 24.76%
Sales past 3/5Y- -
EPS Y/Y TTM26.48%
Sales Y/Y TTM-90.65%
EPS Q/Q40.58%
Sales Q/Q-100.00%
Earnings-
EPS/Sales Surpr.-45.10% -

Ownership

Insider Own24.53%
Insider Trans0.00%
Inst Own11.06%
Inst Trans-4.94%
ROA-80.81%
ROE-99.89%
ROIC-177.35%
Gross Margin36.00%
Oper. Margin-16427.00%
Profit Margin-14621.00%
SMA2014.93%
SMA50-7.35%
SMA200-58.58%
Trades-

Technical

Shs Outstand9.12M
Shs Float8.15M
Short Float0.42%
Short Ratio0.12
Short Interest0.03M
52W High5.07 -76.33%
52W Low0.96 24.95%
Volatility9.98% 8.96%
ATR (14)0.13
RSI (14)54.55
Beta1.01
Rel Volume3.74
Avg Volume283.55K
Volume1,060,394

Performance

Perf Week13.21%
Perf Month11.11%
Perf Quarter6.19%
Perf Half Y-63.41%
Perf YTD-35.48%
Perf Year-42.86%
Perf 3Y-44.70%
Perf 5Y-92.38%
Perf 10Y-97.63%
Recom1.00
Target Price4.00
Prev Close1.02
Price1.20
Change %17.65%

Peers

Mkt cap
TickerCompanyMkt cap
RNXTRenovoRx Inc58.87M
PPCBPropanc Biopharma Inc1.90M
SLXNSilexion Therapeutics Corp2.04M
ELTXElicio Therapeutics Inc46.14M
ONCYOncolytics Biotech Inc52.48M
PMCBPharmaCyte Biotech Inc4.29M
FTHFaeth Therapeutics Inc345.01M
TPSTTempest Therapeutics Inc7.94M
PCSAProcessa Pharmaceuticals Inc5.23M
IMNNImunon Inc4.04M

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B
DCORUS Core Equity 1 Portfolio ETF Class SharesAUM: 3.65B

News

latest 14 of 200

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2025Q42026-02-26-0.740-0.510-0.7400.00-1
2025Q32025-11-06-0.490-0.535-0.4860.000.002
2025Q22025-08-07-0.540-0.650-0.5410.070.002
2025Q12025-05-08-0.550-0.530-0.5490.00-1
2024Q42025-02-27-0.550-0.760-0.5490.000.002
2024Q32024-11-12-0.590-0.750-0.5930.000.002
2024Q22024-08-12-0.610-0.750-0.6070.000.002
2024Q12024-05-09-0.650-0.725-0.6510.000.002
2023Q42024-02-29-0.660-0.855-0.6590.000.002
2023Q32023-11-02-0.650-0.930-0.6460.000.002
2023Q22023-08-14-0.500-0.700-0.5020.000.002
2023Q12023-05-09-0.770-0.810-0.7750.000.001
2022Q42023-03-30-0.760-0.960-0.7620.000.002
2022Q32022-11-10-7.880-1.275-7.8750.000.002
2022Q22022-08-04-1.650-1.725-1.6420.000.002
2022Q12022-05-05-1.050-1.450-1.0470.000.003

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2017FY38.4000.675-48.1070.000.00
2018FY-25.050-25.900-25.0290.000.00
2019FY-28.200-23.625-28.1270.000.00
2020FY-7.950-7.950-7.9180.000.00
2021FY-7.500-7.850-7.4480.000.00
2022FY-10.470-8.090-10.4680.000.00
2023FY-2.580-2.910-2.5810.000.00
2024FY-2.400-2.617-2.3991.000.00
2025FY-2.400-2.325-2.4000.100.00
2026FY--1.090--0.00
2027FY--1.160--0.00
2028FY--0.980--7.20

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026FYS2026-05-141000.000.000.00
2026FYS2025-11-282000.000.000.00
2026FYS2025-11-113000.000.000.00
2026FYS2025-11-103000.000.000.00
2026FYS2025-11-093000.000.000.00
2026FYS2025-11-083000.000.000.00
2026FYS2025-11-073000.000.000.00
2026FYS2025-11-062000.000.000.00
2026FYS2025-11-052000.000.000.00
2026FYS2025-11-042000.000.000.00
2026FYS2025-11-032000.000.000.00
2026FYS2025-11-022000.000.000.00
2026FYS2025-11-012000.000.000.00
2026FYS2025-10-312000.000.000.00

Estimate history

EPS, annual-48.107-25.029-28.127-7.918-7.448-10.468-2.581-2.399-1.909-1.6408
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.607-0.593-0.549-0.549-0.541-0.486-0.334-0.498-0.322
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual000000010.170.1
Period201720182019202020212022202320242025TTM
Sales, quarterly00100.0700.100
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual0.6320.6570.7011.2923.9867.8668.158.4098.8349.119
Period201720182019202020212022202320242025MRQ
Shares, quarterly8.3218.328.4098.628.6268.7568.8349.1079.119
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.100.171.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.060.150.170.190.070.060.060.070.23
Gross Profit0.040.020.83-0.19-0.07-0.06-0.06-0.07-0.23
Selling, General and Administrative Excl. Other16.4618.2323.2325.5227.1429.0020.6822.7319.36
Research and Development4.887.9511.3312.7313.0717.6810.8513.5010.19
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-16.43-18.21-22.41-25.71-27.21-29.05-20.75-22.79-19.59
Interest Expense0.000.000.000.000.000.000.000.000.01
Unusual Expense0.000.000.000.0030.390.000.00--
Net Income Before Taxes-15.01-17.55-20.78-23.17-56.70-28.97-19.01-19.35-16.17
Income Taxes-0.39-0.96-0.80-2.33-2.48-1.51-10.870.000.00
Consolidated Net Income-14.62-16.59-19.98-20.84-54.23-27.47-8.14-19.35-16.17
Net Income From Continuing Operations-14.62-16.59-19.98-20.84-54.23-27.47-8.15-19.36-16.17
Net Income-14.62-16.59-19.98-20.84-54.23-27.47-8.15-19.36-16.17
EPS (Recurring)-1.61-1.91-2.40-2.58-6.36-7.45-7.92-28.13-25.03
EPS (Basic, Before Extraordinaries)-1.64-1.91-2.40-2.58-10.47-7.45-7.92-28.13-25.03
EPS (Diluted)-1.64-1.91-2.40-2.58-10.47-7.45-7.92-28.13-25.03
EBITDA-16.36-18.06-22.23-25.52-27.14-29.00-20.68-22.73-19.36
Non-Operating Income (Expense)1.420.661.632.540.900.081.733.443.42
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.960.971.311.612.082.001.261.291.94
Price To Sales Ratio309.6095.0524.82------
Gross Margin36.0014.1282.60------
Operating Margin-16,427.00-10,711.18-2,240.90------
Net Margin-14,621.00-9,756.47-1,998.50------
Shares Outstanding9.128.838.418.157.873.991.290.700.66
Market Capitalization11.0211.0225.0222.2219.8950.3227.7126.4035.08

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.000.000.100.000.070.001.000.00
Cost of Goods Sold Incl. D&A0.000.000.010.040.040.040.040.04
Gross Profit-0.00-0.000.09-0.040.03-0.040.96-0.04
Selling, General and Administrative Excl. Other3.994.943.164.374.895.805.915.29
Research and Development0.581.201.131.962.252.602.952.54
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-3.99-4.94-3.08-4.41-4.87-5.85-4.95-5.34
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-2.93-4.88-2.95-4.25-4.66-5.69-4.61-4.93
Income Taxes0.00-0.390.000.000.00-0.960.000.00
Consolidated Net Income-2.93-4.49-2.95-4.25-4.66-4.72-4.61-4.93
Net Income From Continuing Operations-2.93-4.49-2.95-4.25-4.66-4.72-4.61-4.93
Net Income-2.93-4.49-2.95-4.25-4.66-4.72-4.61-4.93
EPS (Recurring)-0.32-0.50-0.33-0.49-0.54-0.55-0.55-0.59
EPS (Basic, Before Extraordinaries)-0.32-0.50-0.33-0.49-0.54-0.55-0.55-0.59
EPS (Diluted)-0.32-0.50-0.33-0.49-0.54-0.55-0.55-0.59
EBITDA-3.99-4.94-3.06-4.37-4.82-5.80-4.91-5.29
Non-Operating Income (Expense)1.060.070.120.170.210.160.340.41
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.210.290.230.230.240.420.640.33
Price To Sales Ratio309.60265.4196.6521.4023.3120.2125.04-
Gross Margin--85.00-37.14-95.90-
Operating Margin---3,079.00--6,954.29--494.90-
Net Margin---2,954.00--6,655.71--461.00-
Shares Outstanding9.129.118.838.768.638.628.418.32
Market Capitalization11.0245.2516.4122.9424.9320.2625.0224.96

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments15.9631.2550.5369.2394.9734.5725.1643.0560.09
Short Term Receivables0.701.501.000.000.000.000.000.000.00
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets1.051.832.392.651.210.760.811.051.31
Total Current Assets17.7034.5853.9271.8896.1835.3325.9744.1161.40
Net Property, Plant & Equipment0.020.210.480.780.790.631.010.170.26
Total Investments and Advances0.000.000.000.000.000.000.000.000.00
Intangible Assets0.000.190.260.33-----
Deferred Tax Assets-------0.000.58
Other Assets0.020.020.020.040.040.040.170.311.72
Total Assets17.7435.0054.6973.0397.0136.0027.1544.5863.38
Short Term Debt Incl. Current Port. of LT Debt0.000.140.170.180.230.370.350.000.16
Accounts Payable1.021.282.422.651.931.021.490.761.34
Other Current Liabilities2.054.194.003.552.362.124.134.867.81
Total Current Liabilities3.075.616.596.384.523.515.985.629.31
Long Term Debt0.000.000.140.300.480.250.620.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities0.070.070.070.020.000.000.000.000.00
Total Liabilities3.145.686.806.715.013.766.605.629.31
Non-Equity Reserves0.000.000.000.000.000.000.001.513.87
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity14.8629.5748.1566.5892.2532.5020.8237.7350.51
Total Shareholders Equity14.8629.5748.1566.5892.2532.5020.8237.7350.51
Accumulated Minority Interest-0.25-0.25-0.25-0.25-0.25-0.25-0.26-0.27-0.32
Total Equity14.6029.3247.8966.3292.0032.2420.5537.4550.19
Total Liabilities & Stockholders Equity17.7435.0054.6973.0397.0136.0027.1544.5863.38
Book Value Per Share1.683.525.918.4623.1425.1529.6957.4279.98
Tangible Book Value Per Share1.683.495.888.4223.1425.1529.6957.4279.98
Full-Time Employees212625272724272522
Price to Book Ratio1.130.740.420.280.550.851.270.930.62
Return on Assets-62.89-44.56-32.63-63.78-41.30-25.81-53.98-29.95-27.36
Return on Equity-74.67-51.43-36.33-68.28-44.03-30.57-66.14-36.65-42.76
Return on Invested Capital-111.65-67.58-43.16-81.07-29.62-24.89-90.30-42.85-56.95
Quick Ratio5.766.168.1811.2621.2710.084.357.856.59
Current Ratio5.766.168.1811.2621.2710.084.357.856.59

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-14.62-16.59-19.98-20.84-54.23-27.47-8.14-19.35-16.17
Depreciation0.060.150.170.190.070.060.060.070.23
Other Funds (Non Cash)1.651.781.331.0833.824.521.571.531.31
Funds from Operations-12.91-14.66-18.48-19.57-20.34-22.89-6.51-17.76-14.64
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital0.59-1.29-0.87-0.46-0.830.65-2.32-1.12-5.35
Cash from Operating Activities-12.32-15.95-19.36-20.03-21.17-22.25-8.82-18.88-19.99
Capital Expenditures0.00-0.030.000.00-0.28-0.06-0.020.00-0.13
Net Assets From Acquisitions0.000.000.000.00-3.320.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.002.55
Purchase or Sale of Investments5.1515.1113.2310.1032.52-54.84-7.2621.43-7.12
Purchase of Investments0.00-9.18-55.82-98.48-89.69-179.78-34.80-32.94-69.69
Sale Or Maturity of Investments5.1524.2969.05108.58122.20124.9427.5454.3762.57
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities5.1515.0913.2310.1028.91-54.90-7.2821.43-4.71
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock0.930.850.070.480.0485.5218.731.311.39
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock0.930.850.070.480.0485.5218.731.311.39
Proceedsfrom Stock Options0.590.840.070.320.0485.5018.731.311.03
Issuance or Reduction of Debt, Net0.000.000.000.000.000.000.000.00-0.16
Change in Long Term Debt0.000.000.000.000.000.000.000.00-0.16
Issuance of Long Term Debt0.000.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.00-0.16
Net Financing Active Other Cash Flow-0.16-0.25-0.27-0.09-0.27-0.25-0.15-0.13-0.40
Other Financing Activities Uses-0.16-0.25-0.27-0.09-0.27-0.25-0.15-0.13-0.40
Cash from Financing Activities0.770.60-0.210.39-0.2285.2818.581.180.82
Exchange Rate Effect0.010.01-0.06-0.02-0.01----
Net Change in Cash-6.39-0.25-6.38-9.567.518.132.483.73-23.87
Free Cash Flow-12.32-15.98-19.36-20.03-21.45-22.30-8.84-18.88-20.12
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments10.4413.0615.9619.0021.9725.83
Short Term Receivables0.200.200.701.201.201.35
Inventories0.000.000.000.000.000.00
Other Current Assets0.370.761.051.381.711.43
Total Current Assets11.0114.0217.7021.5724.8928.62
Net Property, Plant & Equipment0.010.020.020.020.100.17
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets0.00-0.000.140.160.17
Other Assets0.000.020.020.020.020.02
Total Assets11.0314.0617.7421.7625.1628.98
Short Term Debt Incl. Current Port. of LT Debt0.000.000.000.000.050.09
Accounts Payable0.840.511.020.620.780.60
Other Current Liabilities2.152.812.053.953.483.11
Total Current Liabilities2.993.313.074.574.313.81
Long Term Debt0.000.000.000.000.000.00
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.050.070.070.070.070.07
Total Liabilities3.043.393.144.644.383.88
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity8.2410.9314.8617.3721.0325.36
Total Shareholders Equity8.2410.9314.8617.3721.0325.36
Accumulated Minority Interest-0.25-0.25-0.25-0.25-0.25-0.25
Total Equity7.9910.6714.6017.1220.7725.10
Total Liabilities & Stockholders Equity11.0314.0617.7421.7625.1628.98
Book Value Per Share0.901.201.681.982.442.94
Tangible Book Value Per Share0.901.201.681.972.422.92
Full-Time Employees--21---
Price to Book Ratio1.132.980.941.070.990.67
Return on Assets-80.81-75.98-62.89-60.85-55.88-50.01
Return on Equity-99.89-90.13-74.67-71.45-63.84-56.49
Return on Invested Capital-35.53-41.09-19.89-24.46-22.16-18.63
Quick Ratio3.694.235.764.725.777.52
Current Ratio3.694.235.764.725.777.52

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-2.93-4.49-2.95-4.25-4.66-4.72
Depreciation0.000.000.010.040.040.04
Other Funds (Non Cash)0.210.360.850.220.220.49
Funds from Operations-2.71-4.12-2.09-3.99-4.40-4.19
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital0.061.04-1.160.650.44-1.21
Cash from Operating Activities-2.65-3.08-3.25-3.34-3.96-5.40
Capital Expenditures0.000.000.000.00-0.030.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.005.150.539.43
Purchase of Investments0.000.000.000.00-4.10-5.08
Sale Or Maturity of Investments0.000.000.005.154.6314.51
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities0.000.000.005.150.519.43
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.030.340.200.350.070.22
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.030.340.200.350.070.22
Proceedsfrom Stock Options0.030.000.200.350.070.21
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.00-0.160.000.00-0.01-0.24
Other Financing Activities Uses0.00-0.160.000.00-0.01-0.24
Cash from Financing Activities0.030.180.200.350.06-0.02
Exchange Rate Effect0.000.010.000.000.010.00
Net Change in Cash-2.62-2.90-3.042.16-3.384.01
Free Cash Flow-2.65-3.08-3.25-3.34-3.98-5.40

Revenue breakdown

Pharmaceutical Preparations2024: 1.00M 2025: 170.00K
United States2024: 1.00M 2025: 170.00K

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-300.42%0.0M8.2M285.62K
2026-10-150.35%0.0M8.2M304.04K
2026-09-300.58%0.0M6.9M289.84K
2026-09-152.41%0.2M6.9M233.13K
2026-08-312.06%0.1M6.9M237.45K
2026-08-141.23%0.1M7.3M125.23K
2026-07-310.77%0.1M7.3M118.15K
2026-07-151.75%0.1M7.4M105.12K
2026-06-301.41%0.1M7.4M112.46K
2026-06-151.21%0.1M7.4M116.87K
2026-05-291.68%0.1M7.4M97.61K
2026-05-151.27%0.1M7.4M73.10K
2026-04-300.95%0.1M7.4M85.15K
2026-04-150.70%0.1M7.3M183.30K
2026-03-310.23%0.0M7.3M173.95K
2026-03-130.20%0.0M7.3M170.07K
2026-02-270.21%0.0M7.1M153.43K
2026-02-130.42%0.0M7.1M149.65K
2026-01-300.39%0.0M7.1M173.38K
2026-01-150.11%0.0M7.1M68.18K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-09DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-11-098-KCurrent report2026-11-09SEC
2026-10-19ARSAnnual report to security holders. 2025-12-31SEC
2026-10-19DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-11-09SEC
2026-10-153Initial statement of beneficial ownership of securities2026-10-13SEC
2026-10-148-KCurrent report2026-10-13SEC
2026-10-07PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-11-09SEC
2026-10-02DNotice of sales of securities on Form D (Regulation D)SEC
2026-09-283Initial statement of beneficial ownership of securities2026-09-17SEC
2026-09-283Initial statement of beneficial ownership of securities2026-09-17SEC
2026-09-178-KCurrent report2026-09-17SEC
2026-08-26SCHEDULE 13GSEC
2026-08-0610-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-048-KCurrent report2026-08-03SEC
2026-07-28SC TO-T/ASEC
2026-07-248-KCurrent report2026-07-24SEC
2026-07-21SC 14D9/ASEC
2026-07-178-KCurrent report2026-07-16SEC
2026-07-17SC 14D9/ASEC
2026-07-17SC TO-T/ASEC
2026-07-13SC 14D9/ASEC
2026-07-10SC TO-T/ASEC
2026-07-02SC 14D9/ASEC
2026-06-10SC 14D9Tender offer solicitation / recommendation statements filed under Rule 14-d9SEC
2026-06-10SC TO-TThird party tender offer statementSEC
2026-06-09SC14D9CWritten communication by the subject company relating to a third party tender offerSEC
2026-06-098-KCurrent report2026-06-08SEC
2026-06-01SC TO-CWritten communication relating to an issuer or third party tender offerSEC
2026-06-01SC14D9CWritten communication by the subject company relating to a third party tender offerSEC
2026-06-018-KCurrent report2026-06-01SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
VANGUARD CAPITAL MANAGEMENT LLC3.06%
Yakira Capital Management, Inc.1.52%
Deeter Investments LLP1.31%
CSS LLC/IL1.21%
Rangeley Capital, LLC0.89%
GEODE CAPITAL MANAGEMENT, LLC0.81%
DELTEC ASSET MANAGEMENT LLC0.70%
Virtu Financial LLC0.65%
BlackRock, Inc.0.60%
VANGUARD FIDUCIARY TRUST CO0.54%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND2.10%
VANGUARD EXTENDED MARKET INDEX FUND0.88%
Fidelity Extended Market Index Fund0.42%
Fidelity Series Total Market Index Fund0.12%
VANGUARD BALANCED INDEX FUND0.08%
Fidelity Nasdaq Composite Index Fund0.05%
Fidelity Total Market Index Fund0.05%
U.S. Social Core Equity 2 Portfolio0.02%
Dimensional US Sustainability Core 1 ETF0.00%
Dimensional US Core Equity 1 ETF0.00%

OakChart. LSTA. Cached 15 minutes.

Some panels did not load: ratings, insider.